Infinity Pharmaceuticals, Inc.

Lawrence K Chan

Alfredo C Castro

Stephane Peluso

Thomas T Tibbitts

Daniel A Snyder

Louis Grenier

Michael J Grogan

Catherine Anne Evans

Yves Leblanc

Tao Liu

Mark L Behnke

Gregg F Keaney

Marta Nevalainen

Adilah Bahadoor

Vesa Nevalainen

Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables R, Rand Rare defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Tetrazolones as inhibitors of fatty acid synthase

The present invention provides isoxazoline FAAH inhibitors of the formula (I):  The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

Isoxazolines as inhibitors of fatty acid amide hydrolase

Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables R, X, R, and Rare defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Triazoles as inhibitors of fatty acid synthase

Growing community of inventors

Brookline, MA, United States of America

Lawrence K Chan